RCUSEarnings•businesswire•
Arcus Biosciences Reports Second-Quarter 2025 Financial Results and Provides a Pipeline Update
Sentiment:Negative (30)
Summary
HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for patients with cancer, today reported financial results for the second quarter ended June 30, 2025, and provided a pipeline update on its clinical-stage investigational molecules across multiple common cancers. “We have now presented data from over 125 patients treated with casdatifan monotherapy or
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on August 6, 2025 by businesswire